Chief Financial Officer · Aclaris Therapeutics, Inc. · Common Stock
Side
M
Value
—
Shares
22.0K
Price
—
Executed
Feb 3, 2026
Disclosed
Feb 5, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 3 executedFeb 5, 2026 disclosed
ACRS · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 12.9% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Balthaser Kevin filed this Form 4 reporting a option exercise of ACRS on Feb 3, 2026. It became public on Feb 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Balthaser Kevincik:0001957554
Issuer
Aclaris Therapeutics, Inc.cik:0001557746
Revision history · 0
No field has changed since this record was first ingested.
